BRPI0408247A - usos de antagonistas e agonistas de il-23 e reagentes relacionados - Google Patents

usos de antagonistas e agonistas de il-23 e reagentes relacionados

Info

Publication number
BRPI0408247A
BRPI0408247A BRPI0408247-8A BRPI0408247A BRPI0408247A BR PI0408247 A BRPI0408247 A BR PI0408247A BR PI0408247 A BRPI0408247 A BR PI0408247A BR PI0408247 A BRPI0408247 A BR PI0408247A
Authority
BR
Brazil
Prior art keywords
agonists
antagonists
related reagents
methods
reagents
Prior art date
Application number
BRPI0408247-8A
Other languages
English (en)
Inventor
Martin Oft
Terrill K Mcclanahan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0408247A publication Critical patent/BRPI0408247A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"USOS DE ANTAGONISTAS E AGONISTAS DE IL-23 E REAGENTES RELACIONADOS". A presente invenção refere-se a métodos de tratamento para tumores. Em particular, métodos que são providos para a modulação de atividade de uma molécula de citocina e seu receptor.
BRPI0408247-8A 2003-03-10 2004-03-09 usos de antagonistas e agonistas de il-23 e reagentes relacionados BRPI0408247A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Publications (1)

Publication Number Publication Date
BRPI0408247A true BRPI0408247A (pt) 2006-03-01

Family

ID=32990805

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408247-8A BRPI0408247A (pt) 2003-03-10 2004-03-09 usos de antagonistas e agonistas de il-23 e reagentes relacionados

Country Status (22)

Country Link
US (4) US7282204B2 (pt)
EP (2) EP2108658B1 (pt)
JP (4) JP4605798B2 (pt)
CN (1) CN1759123B (pt)
AT (1) ATE440864T1 (pt)
AU (2) AU2004219625B9 (pt)
BR (1) BRPI0408247A (pt)
CA (1) CA2518262C (pt)
CL (1) CL2004000467A1 (pt)
CY (1) CY1109468T1 (pt)
DE (1) DE602004022781D1 (pt)
DK (1) DK1601694T3 (pt)
ES (1) ES2330220T3 (pt)
MX (1) MXPA05009717A (pt)
NO (1) NO20054630D0 (pt)
NZ (2) NZ541898A (pt)
PL (1) PL1601694T3 (pt)
PT (1) PT1601694E (pt)
SI (1) SI1601694T1 (pt)
TW (2) TWI357336B (pt)
WO (1) WO2004081190A2 (pt)
ZA (1) ZA200506879B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2108660A1 (en) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
SI1601694T1 (sl) * 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
WO2004101750A2 (en) * 2003-05-09 2004-11-25 Centocor, Inc. IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
AU2005215527B2 (en) * 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
EP1756138A4 (en) * 2004-03-05 2009-07-01 Archemix Corp APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2292758A3 (en) * 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
AU2006265898A1 (en) * 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the IL-12 family of cytokines
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
AU2006283194B9 (en) * 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
EP2322219A3 (en) 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
EP2057194B1 (en) 2007-02-28 2013-03-20 Merck Sharp & Dohme Corp. Engineered anti-il-23r antibodies
WO2009007849A2 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
ES2469802T3 (es) * 2008-10-20 2014-06-20 Valipharma Métodos y usos que implican aberraciones genéticas de NAV 3 y expresión aberrante de múltiples genes
CA2757237A1 (en) * 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US8137671B2 (en) * 2009-05-05 2012-03-20 Genentech, Inc. Anti-IL-17F antibodies
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
IL321788A (en) 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US11279754B2 (en) 2015-03-11 2022-03-22 Rush University Medical Center Compositions and methods for treating cancer
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
IL276896B2 (en) 2018-03-05 2024-06-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
WO2021212083A2 (en) * 2020-04-17 2021-10-21 The Board Of Trustees Of The Leland Stanford Junior University Engineered il-12 and il-23 polypeptides and uses thereof
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
CA2352572C (en) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
HK1044170B (en) * 1999-09-09 2008-08-01 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
CZ304022B6 (cs) * 2000-05-10 2013-08-28 Merck Sharp & Dohme Corp. Savcí receptorové proteiny, cinidla a metody, které se jich týkají
CA2425169A1 (en) * 2000-10-06 2002-04-11 Immunex Corporation Hematopoietin receptors hpr1 and hpr2
AU2002314825A1 (en) * 2001-05-30 2002-12-09 Centocor, Inc. Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
SI1601694T1 (sl) * 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti

Also Published As

Publication number Publication date
US20080057058A1 (en) 2008-03-06
NZ541898A (en) 2008-07-31
CN1759123A (zh) 2006-04-12
DK1601694T3 (da) 2009-12-14
JP4605798B2 (ja) 2011-01-05
DE602004022781D1 (de) 2009-10-08
TWI357336B (en) 2012-02-01
CL2004000467A1 (es) 2005-05-06
MXPA05009717A (es) 2005-10-18
CA2518262A1 (en) 2004-09-23
US20120034219A1 (en) 2012-02-09
AU2004219625A1 (en) 2004-09-23
JP2007197453A (ja) 2007-08-09
PL1601694T3 (pl) 2010-02-26
US20100003251A1 (en) 2010-01-07
NO20054630L (no) 2005-10-07
WO2004081190A3 (en) 2005-02-03
CY1109468T1 (el) 2014-08-13
NO20054630D0 (no) 2005-10-07
SI1601694T1 (sl) 2010-01-29
AU2010212372A1 (en) 2010-09-09
TWI439285B (zh) 2014-06-01
EP1601694B1 (en) 2009-08-26
AU2004219625B9 (en) 2010-12-23
CA2518262C (en) 2014-05-06
PT1601694E (pt) 2009-12-03
US7282204B2 (en) 2007-10-16
NZ567860A (en) 2009-11-27
AU2010212372B2 (en) 2012-12-20
JP2014005286A (ja) 2014-01-16
JP2006520781A (ja) 2006-09-14
TW200505479A (en) 2005-02-16
EP2108658A1 (en) 2009-10-14
US8034341B2 (en) 2011-10-11
EP1601694A2 (en) 2005-12-07
ZA200506879B (en) 2006-05-31
CN1759123B (zh) 2011-04-13
EP2108658B1 (en) 2016-06-08
ES2330220T3 (es) 2009-12-07
US20040223969A1 (en) 2004-11-11
HK1076477A1 (en) 2006-01-20
WO2004081190A2 (en) 2004-09-23
TW201141521A (en) 2011-12-01
JP2011032275A (ja) 2011-02-17
ATE440864T1 (de) 2009-09-15
AU2004219625B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
SE0301653D0 (sv) Novel compounds
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
BRPI0412411A (pt) tetrahidro-1h-pirazol[3,4-c]piridinas substituìdas, composições que as contêm e utilização
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
BRPI0400659A (pt) Ativador, sistema de relaxamento e relaxante para os cabelos
SE0300457D0 (sv) Novel compounds
DK1613571T3 (da) Deutererede catecholaminderivater og lægemidler indeholdende disse forbidelser
BR0313307A (pt) Antagonistas do receptor de mcp-1 e método para a sua utilização

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]